All In Biotech

Investigational drug · Phase 3

Debio 4126

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acromegaly.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "Debio 4126"

First trial start

2025

Nov 26, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Debio 4126", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acromegaly

Approved drugs for the same conditions: Acromegaly · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "Debio 4126" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Acromegaly

  • CAM2029octreotide depotPhase 33 trials

    Camurus AB · Polycystic Liver Disease, Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly

  • SYHX2008Phase 33 trials

    CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Diagnosed With Acromegaly, Currently in the Active Stage of the Disease, Gastrointestinal Neuroendocrine Pancreatic Tumor, Acromegaly

  • MAR002Phase 21 trial

    Marea Therapeutics · Acromegaly

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.